• MJHLS Brand Logo

© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in Europe and Latin America.

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22, 2025

Reducing Financial Toxicity in GI Cancer Care Through Biosimilars

January 5th 2025

By Skylar Jeremias

Video

Tiago Biachi, MD, PhD, emphasizes that biosimilars are vital for reducing financial toxicity and ensuring equitable, affordable access to advanced treatments in gastrointestinal (GI) cancer care, while calling for dynamic policies and greater cost awareness among clinicians.

Etanercept and Infliximab Biosimilars Show No Increased Infection Risk, Comparable Safety

January 4th 2025

By Cameron Santoro

Article

No significant difference in the risk of serious infections between etanercept and infliximab biosimilars and their original brand-name medications was identified.

The Top 5 Biosimilar Articles for the Week of December 30

January 3rd 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of December 30, 2024.

Senators Introduce Bipartisan Legislation to Protect Skinny Labeling

January 2nd 2025

By Skylar Jeremias

Article

To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.

Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC

January 1st 2025

By Courtney Flaherty

Article

First-line cetuximab beta injection has received NMPA marketing approval in RAS/BRAF wild-type metastatic colorectal cancer.

The Top 5 Most-Read Biosimilar Articles of 2024

December 31st 2024

By Skylar Jeremias

Article

The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with projections indicating strong uptake in biosimilars at the expense of the originator products, despite challenges like uptake disparities and safety concerns.

The Top 5 Most-Read Ophthalmology Articles of 2024

December 30th 2024

By Skylar Jeremias

Article

The 2024 surge in FDA approvals for aflibercept biosimilars reflects significant progress in offering cost-effective treatments for retinal conditions like neovascular age-related macular degeneration, although patent disputes pose challenges to their market entry and adoption.

Top 5 Most-Read Rheumatology Articles of 2024

December 30th 2024

By Skylar Jeremias

Article

The top 5 rheumatology biosimilar articles of 2024 highlight significant FDA approvals, including high-concentration adalimumab and tocilizumab biosimilars, along with evidence supporting the safety and efficacy of biosimilar-to-biosimilar switching.

The Top 5 Most-Listened to Podcasts of 2024

December 29th 2024

By Skylar Jeremias

Article

On this episode of Not So Different, we reflect on 2024 and this show in particular, taking audiences back through the most popular podcast episodes of the year.

The Top 5 Most-Read Policy Articles of 2024

December 28th 2024

By Skylar Jeremias

Article

The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, alongside challenges posed by pharmacy benefit manager rebate practices and the need for more active stakeholder engagement.